Downregulation of TACC3 inhibits tumor growth and migration in osteosarcoma cells through regulation of the NF-κB signaling pathway

Zhao,Congran; He,Xiaofeng; Li,Heng; Zhou,Jihui; Han,Xiuying; Wang,Dongjun; Tian,Guofeng; Sui,Fuge

doi:10.3892/ol.2018.8262

Downregulation of TACC3 inhibits tumor growth and migration in osteosarcoma cells through regulation of the NF-κB signaling pathway

Authors:
- Congran Zhao
- Xiaofeng He
- Heng Li
- Jihui Zhou
- Xiuying Han
- Dongjun Wang
- Guofeng Tian
- Fuge Sui
View Affiliations

Affiliations: Department of Orthopedics, Daqing Longnan Hospital, Daqing, Heilongjiang 163453, P.R. China
Published online on: March 14, 2018 https://doi.org/10.3892/ol.2018.8262
Pages: 6881-6886
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

TACC3, a member of the transforming acidic coiled-coil protein (TACC) family, is a multifunctional protein that is involved in various biological functions, including proliferation and differentiation of tumor cells, cancer progression and metastasis. The aims of the present study were to examine whether TACC3 expression is associated with the proliferation and migration of osteosarcoma (OS) cells and to investigate the potential underlying molecular mechanisms of TACC3 in OS. First, the levels of mRNA and protein expression in OS cell lines by reverse transcription-quantitative polymerase chain reaction and western blotting, respectively were examined. Second, the effects of TACC3 knockdown and overexpression on the proliferative, migratory and invasive capacities of OS cells were investigated. Finally, western blot analysis was employed to detect the potential mechanism of TACC3 in osteosarcoma. TACC3 expression was significantly increased in osteosarcoma tissues and cell lines, compared to matched controls. The knockdown of TACC3 was able to significantly inhibit the proliferation, migration and invasion of osteosarcoma cells, whereas the overexpression of TACC3 was able to promote cell proliferation and migration. Mechanistically, TACC3 may promote the migration and invasion of osteosarcoma cells via through nuclear factor‑κB signaling. These data suggest that TACC3 has an important part in the progression of osteosarcoma and may serve as a potential target for gene therapy.

View Figures

View References

1	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
2	Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, et al: Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 23:8845–8852. 2005. View Article : Google Scholar : PubMed/NCBI
3	Lu J, Song G, Tang Q, Zou C, Han F, Zhao Z, Yong B, Yin J, Xu H, Xie X, et al: IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-κB signaling. J Clin Invest. 125:1839–1856. 2015. View Article : Google Scholar : PubMed/NCBI
4	Hou CH, Lin FL, Hou SM and Liu JF: Cyr61 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by Raf-1/MEK/ERK/Elk-1/TWIST-1 signaling pathway. Mol Cancer. 13:2362014. View Article : Google Scholar : PubMed/NCBI
5	Tsai HC, Su HL, Huang CY, Fong YC, Hsu CJ and Tang CH: CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d. Oncotarget. 5:3800–3812. 2014. View Article : Google Scholar : PubMed/NCBI
6	Still IH, Vince P and Cowell JK: The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. Genomics. 58:165–170. 1999. View Article : Google Scholar : PubMed/NCBI
7	Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, Thorleifsson G, Gudbjartsson DF, Stacey SN, Gudmundsson J, Zanon C, et al: A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet. 42:415–419. 2010. View Article : Google Scholar : PubMed/NCBI
8	Hood FE and Royle SJ: Pulling it together: The mitotic function of TACC3. Bioarchitecture. 1:105–109. 2011. View Article : Google Scholar : PubMed/NCBI
9	Sadek CM, Pelto-Huikko M, Tujague M, Steffensen KR, Wennerholm M and Gustafsson JA: TACC3 expression is tightly regulated during early differentiation. Gene Expr Patterns. 3:203–211. 2003. View Article : Google Scholar : PubMed/NCBI
10	Yao R, Natsume Y and Noda T: TACC3 is required for the proper mitosis of sclerotome mesenchymal cells during formation of the axial skeleton. Cancer Sci. 98:555–562. 2007. View Article : Google Scholar : PubMed/NCBI
11	Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park SI, Kim J, Sasaki H, Jablons DM, Lipson D, Young L, et al: Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res. 20:6551–6558. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhou DS, Wang HB, Zhou ZG, Zhang YJ, Zhong Q, Xu L, Huang YH, Yeung SC, Chen MS and Zeng MS: TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma. Oncotarget. 6:24163–24177. 2015. View Article : Google Scholar : PubMed/NCBI
13	Zhao Z, Wu MS, Zou C, Tang Q, Lu J, Liu D, Wu Y, Yin J, Xie X, Shen J, et al: Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-κB pathway. Cancer Lett. 342:150–158. 2014. View Article : Google Scholar : PubMed/NCBI
14	Schon S, Flierman I, Ofner A, Stahringer A, Holdt LM, Kolligs FT and Herbst A: β-catenin regulates NF-κB activity via TNFRSF19 in colorectal cancer cells. Int J Cancer. 135:1800–1811. 2014. View Article : Google Scholar : PubMed/NCBI
15	Bera A, Ghosh-Choudhury N, Dey N, Das F, Kasinath BS, Abboud HE and Choudhury GG: NFκB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation. Cell Signal. 25:2575–2586. 2013. View Article : Google Scholar : PubMed/NCBI
16	Shao N, Lu Z, Zhang Y, Wang M, Li W, Hu Z, Wang S and Lin Y: Interleukin-8 upregulates integrin 3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-κB pathway. Cancer Lett. 364:165–172. 2015. View Article : Google Scholar : PubMed/NCBI
17	Korber MI, Staribacher A, Ratzenbock I, Steger G and Mader RM: NFκB-Associated pathways in progression of chemoresistance to 5-fluorouracil in an in vitro model of colonic carcinoma. Anticancer Res. 36:1631–1639. 2016.PubMed/NCBI
18	Tang QL, Xie XB, Wang J, Chen Q, Han AJ, Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, et al: Glycogen synthase kinase-3, NF-κB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst. 104:749–763. 2012. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Ha GH, Park JS and Breuer EK: TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways. Cancer Lett. 332:63–73. 2013. View Article : Google Scholar : PubMed/NCBI
21	Lauffart B, Vaughan MM, Eddy R, Chervinsky D, DiCioccio RA, Black JD and Still IH: Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC Women's Health. 5:82005. View Article : Google Scholar
22	Yun M, Rong J, Lin ZR, He YL, Zhang JX, Peng ZW, Tang LQ, Zeng MS, Zhong Q and Ye S: High expression of transforming acidic coiled coil-containing protein 3 strongly correlates with aggressive characteristics and poor prognosis of gastric cancer. Oncol Rep. 34:1397–1405. 2015. View Article : Google Scholar : PubMed/NCBI
23	Jiang F, Kuang B, Que Y, Lin Z, Yuan L, Xiao W, Peng R and Zhang X and Zhang X: The clinical significance of transforming acidic coiled-coil protein 3 expression in non-small cell lung cancer. Oncol Rep. 35:436–446. 2016. View Article : Google Scholar : PubMed/NCBI
24	Nahm JH, Kim H, Lee H, Cho JY, Choi YR, Yoon YS, Han HS and Park YN: Transforming acidic coiled-coil-containing protein 3 (TACC3) overexpression in hepatocellular carcinomas is associated with ‘stemness’ and epithelial-mesenchymal transition-related marker expression and a poor prognosis. Tumour Biol. 37:393–403. 2016. View Article : Google Scholar : PubMed/NCBI
25	Huang ZL, Lin ZR, Xiao YR, Cao X, Zhu LC, Zeng MS, Zhong Q and Wen ZS: High expression of TACC3 in esophageal squamous cell carcinoma correlates with poor prognosis. Oncotarget. 6:6850–6861. 2015. View Article : Google Scholar : PubMed/NCBI
26	Ha GH, Kim JL and Breuer EK: TACC3 is essential for EGF-mediated EMT in cervical cancer. PLoS One. 8:e703532013. View Article : Google Scholar : PubMed/NCBI